Distribution of Misfolded Prion Protein Seeding Activity Alone Does Not Predict Regions of Neurodegeneration

Protein misfolding is common across many neurodegenerative diseases, with misfolded proteins acting as seeds for "prion-like" conversion of normally folded protein to abnormal conformations. A central hypothesis is that misfolded protein accumulation, spread, and distribution are restricted to specific neuronal populations of the central nervous system and thus predict regions of neurodegeneration. We examined this hypothesis using a highly sensitive assay system for detection of misfolded protein seeds in a murine model of prion disease. Misfolded prion protein (PrP) seeds were observed widespread throughout the brain, accumulating in all brain regions examined irrespective of neurodegeneration. Importantly, neither time of exposure nor amount of misfolded protein seeds present determined regions of neurodegeneration. We further demonstrate two distinct microglia responses in prion-infected brains: a novel homeostatic response in all regions and an innate immune response restricted to sites of neurodegeneration. Therefore, accumulation of misfolded prion protein alone does not define targeting of neurodegeneration, which instead results only when misfolded prion protein accompanies a specific innate immune response.

[1]  B. McColl,et al.  Defining the Microglia Response during the Time Course of Chronic Neurodegeneration , 2015, Journal of Virology.

[2]  Tom Michoel,et al.  Microglial brain region-dependent diversity and selective regional sensitivities to ageing , 2015, Nature Neuroscience.

[3]  Michel Goedert,et al.  Alzheimer’s and Parkinson’s diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein , 2015, Science.

[4]  Mathias Jucker,et al.  Neurodegenerative diseases: expanding the prion concept. , 2015, Annual review of neuroscience.

[5]  J. Trojanowski,et al.  Spreading of pathology in neurodegenerative diseases: a focus on human studies , 2015, Nature Reviews Neuroscience.

[6]  C. de Wolf,et al.  Prion Protein-Specific Antibodies that Detect Multiple TSE Agents with High Sensitivity , 2014, PloS one.

[7]  J. Ironside,et al.  Molecular Barriers to Zoonotic Transmission of Prions , 2014, Emerging infectious diseases.

[8]  V. Sim,et al.  Early Increase and Late Decrease of Purkinje Cell Dendritic Spine Density in Prion-Infected Organotypic Mouse Cerebellar Cultures , 2013, PloS one.

[9]  M. Horiuchi,et al.  Absence of CD14 Delays Progression of Prion Diseases Accompanied by Increased Microglial Activation , 2013, Journal of Virology.

[10]  H. Kretzschmar,et al.  Comparative Analysis of Gene Expression Profiles Between Cortex and Thalamus in Chinese Fatal Familial Insomnia Patients , 2013, Molecular Neurobiology.

[11]  V. Perry,et al.  Regulation of Microglial Proliferation during Chronic Neurodegeneration , 2013, The Journal of Neuroscience.

[12]  B. Caughey,et al.  Prion Seeding Activities of Mouse Scrapie Strains with Divergent PrPSc Protease Sensitivities and Amyloid Plaque Content Using RT-QuIC and eQuIC , 2012, PloS one.

[13]  Emily V. Chambers,et al.  Mechanism of PrP‐Amyloid Formation in Mice Without Transmissible Spongiform Encephalopathy , 2012, Brain pathology.

[14]  M. Jucker,et al.  Pathogenic protein seeding in alzheimer disease and other neurodegenerative disorders , 2011, Annals of neurology.

[15]  B. Caughey,et al.  Prion Disease Blood Test Using Immunoprecipitation and Improved Quaking-Induced Conversion , 2011, mBio.

[16]  Steven J Collins,et al.  Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion , 2011, Nature Medicine.

[17]  Brent Race,et al.  Rapid End-Point Quantitation of Prion Seeding Activity with Sensitivity Comparable to Bioassays , 2010, PLoS pathogens.

[18]  Melinda E. Lull,et al.  Microglial activation and chronic neurodegeneration , 2010, Neurotherapeutics.

[19]  P. Greengard,et al.  Writing Memories with Light-Addressable Reinforcement Circuitry , 2009, Cell.

[20]  S. Norley,et al.  Accelerated Prion Replication in, but Prolonged Survival Times of, Prion-Infected CXCR3−/− Mice , 2008, Journal of Virology.

[21]  Richard C. Moore,et al.  Genes contributing to prion pathogenesis. , 2008, The Journal of general virology.

[22]  B. Chesebro,et al.  Role of Erk1/2 activation in prion disease pathogenesis: Absence of CCR1 leads to increased Erk1/2 activation and accelerated disease progression , 2008, Journal of Neuroimmunology.

[23]  A. Su,et al.  Expression analysis of G Protein-Coupled Receptors in mouse macrophages , 2008, Immunome research.

[24]  Sarah Medina,et al.  Comprehensive transcriptional profiling of prion infection in mouse models reveals networks of responsive genes , 2008, BMC Genomics.

[25]  Claudio Soto,et al.  Protein misfolding and neurodegeneration. , 2008, Archives of neurology.

[26]  Declan King,et al.  High Titers of Transmissible Spongiform Encephalopathy Infectivity Associated with Extremely Low Levels of PrPSc in Vivo* , 2007, Journal of Biological Chemistry.

[27]  B. Ghetti,et al.  Accumulation of prion protein in the brain that is not associated with transmissible disease , 2007, Proceedings of the National Academy of Sciences.

[28]  Jacques van Helden,et al.  Evaluation of clustering algorithms for protein-protein interaction networks , 2006, BMC Bioinformatics.

[29]  V. Perry,et al.  TGFβ1 regulates the inflammatory response during chronic neurodegeneration , 2006, Neurobiology of Disease.

[30]  Pamela J Skinner,et al.  Gene expression alterations in brains of mice infected with three strains of scrapie , 2006, BMC Genomics.

[31]  V. Perry,et al.  MCP-1 and murine prion disease: Separation of early behavioural dysfunction from overt clinical disease , 2005, Neurobiology of Disease.

[32]  G. J. Raymond,et al.  The most infectious prion protein particles , 2005, Nature.

[33]  H. Kretzschmar,et al.  Cerebral gene expression profiles in sporadic Creutzfeldt–Jakob disease , 2005, Annals of neurology.

[34]  Angus Lauder,et al.  Accelerated Prion Disease in the Absence of Interleukin-10 , 2004, Journal of Virology.

[35]  V. Perry,et al.  Synaptic changes characterize early behavioural signs in the ME7 model of murine prion disease , 2003, The European journal of neuroscience.

[36]  S. Leurgans,et al.  Tau Conformational Changes Correspond to Impairments of Episodic Memory in Mild Cognitive Impairment and Alzheimer's Disease , 2002, Experimental Neurology.

[37]  B. Permanne,et al.  Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding , 2001, Nature.

[38]  R B Banati,et al.  The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. , 2000, Brain : a journal of neurology.

[39]  A. Johnston,et al.  Synapse loss associated with abnormal PrP precedes neuronal degeneration in the scrapie‐infected murine hippocampus , 2000, Neuropathology and applied neurobiology.

[40]  I. Mcconnell,et al.  A single amino acid alteration (101L) introduced into murine PrP dramatically alters incubation time of transmissible spongiform encephalopathy , 1999, The EMBO journal.

[41]  D. Selkoe,et al.  Translating cell biology into therapeutic advances in Alzheimer's disease , 1999, Nature.

[42]  J. Morris,et al.  Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.

[43]  M. Gurney,et al.  Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS , 1998 .

[44]  J. Rossier,et al.  Transmission of the BSE Agent to Mice in the Absence of Detectable Abnormal Prion Protein , 1997, Science.

[45]  A. Aguzzi,et al.  Normal host prion protein necessary for scrapie-induced neurotoxicity , 1996, Nature.

[46]  J Carter,et al.  Molecular Pathology of Alzheimer's Disease , 2013 .

[47]  I. Mcconnell,et al.  129/Ola mice carrying a null mutation in PrP that abolishes mRNA production are developmentally normal , 1994, Molecular Neurobiology.

[48]  A. Aguzzi,et al.  Mice devoid of PrP are resistant to scrapie , 1993, Cell.

[49]  Edward M. Reingold,et al.  Graph drawing by force‐directed placement , 1991, Softw. Pract. Exp..

[50]  D. Selkoe,et al.  Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease , 1989, Journal of Neuroimmunology.

[51]  P. Mcgeer,et al.  Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.

[52]  S. Prusiner,et al.  A protease-resistant protein is a structural component of the Scrapie prion , 1983, Cell.

[53]  E. Manning,et al.  Early distribution of radioactive liposomes and scrapie infectivity in mouse tissues following administration by different routes , 1979 .

[54]  H. Fraser,et al.  Identification of a gene which controls the incubation period of some strains of scrapie agent in mice. , 1968, Journal of comparative pathology.

[55]  H. Fraser,et al.  Distribution of Experimentally Induced Scrapie Lesions in the Brain , 1967, Nature.

[56]  T. Michoel,et al.  Microglial brain regiondependent diversity and selective regional sensitivities to aging , 2015 .

[57]  Anton J. Enright,et al.  Network visualization and analysis of gene expression data using BioLayout Express3D , 2009, Nature Protocols.

[58]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[59]  M. Gurney,et al.  Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. , 1998, Glia.